Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prussian Blue Nanozyme Potentiates Venetoclax Efficacy in Acute Myeloid Leukemia by Inducing a More Mature Phenotype.

International journal of nanomedicine - 1 Jan 2026

Yang Fan, Wu Hang, Yao Jing, Peng Xuelu, Yang Aiyun, Wen Tao, Meng Jie, Liu Jian, Zhang Yu, Wang Tao, Xu Haiyan

Abstract excerpt

Introduction: Acute Myeloid Leukemia (AML) is characterized by the clonal expansion of undifferentiated myeloid precursors and is associated with notably higher incidence and mortality rates in the elderly population. While the BCL-2 inhibitor Venetoclax has transformed the therapeutic landscape for patients with AML who were ineligible for intensive therapy, primary and acquired resistance remained major...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Membrane Potential, Mitochondrial

Share to Nanoparticles

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 42226963
DOI: 10.2147/IJN.S601085
PMCID: PMC13222633

Genes

CD14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 12 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prussian Blue Nanozyme Potentiates Venetoclax Efficacy in Acute Myeloid Leukemia by Inducing a More Mature Phenotype.PMID 42226963Read ↗

Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?Semantic proximity Read ↗

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALLSemantic proximity Read ↗

The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and SafetySemantic proximity Read ↗

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative PhosphorylationSemantic proximity Read ↗

Realgar transforming solution suppresses KG-1a-derived CD34+CD38- acute myeloid leukemia stem cell-like phenotypes in association with ER-mitochondrial stress and mitophagy-related alterations.Semantic proximity Read ↗

Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteinsSemantic proximity Read ↗

ZnO Q-Dots Nanoparticles: Intensifying ROS Stress to Improve Anticancer Drug EfficacySemantic proximity Read ↗

Parthanatos-inducing zinc agent C010DS-Zn elicits anti-tumor immune responses involving T cells and macrophages <i>in vivo</i>Semantic proximity Read ↗

Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication GenesSemantic proximity Read ↗

A Phenotypic Screen Identifies a Compound Series That Induces Differentiation of Acute Myeloid Leukemia Cells In Vitro and Shows Antitumor Effects In Vivo.Semantic proximity Read ↗

Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemiaSemantic proximity Read ↗

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.